Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$55.88 – $60.00
51% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.35B | $1.48B | $1.45B | $1.58B | $1.85B | $2.08B | $2.34B | $2.62B |
| Cost of revenue | $395.6M | $436.9M | $406.8M | $427.7M | $566.7M | $600.8M | $741.3M | $830.7M |
| Gross profit | $956.7M | $1.04B | $1.04B | $1.15B | $1.29B | $1.48B | $1.60B | $1.79B |
| Gross margin | 70.7% | 70.5% | 71.9% | 72.9% | 69.4% | 71.1% | 68.3% | 68.3% |
| R&D | $109.7M | $129.7M | $146.2M | $166.1M | $220.1M | $255.7M | $286.0M | $341.0M |
| Operating income | $442.2M | $465.3M | $469.0M | $490.2M | $437.3M | $558.0M | $638.9M | $719.7M |
| EBITDA | $501.5M | $537.4M | $566.8M | $578.4M | $559.3M | $708.6M | $795.8M | $887.0M |
| Net income | $312.4M | $368.8M | $355.0M | $386.0M | $312.3M | $389.2M | $416.5M | $443.6M |
| Net margin | 23.1% | 24.9% | 24.5% | 24.4% | 16.9% | 18.7% | 17.8% | 16.9% |
| EPS (diluted) | 1.49 | 1.76 | 1.70 | 1.85 | 1.49 | 1.86 | 1.99 | 2.12 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.8B | $3.09 | $3.01–$3.19 | 1 |
| 2027 | $3.0B | $3.58 | $3.49–$3.69 | 1 |
| 2028 | $3.2B | $4.02 | $3.91–$4.14 | 1 |
| 2029 | $3.7B | $5.11 | $4.97–$5.26 | 1 |
Forward consensus · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| RCDTFRecordati S.p.A. | $58.00 | +0.00% | $11.8B | — |
| BDULFBangkok Dusit Medical Services Public Company Limited | $0.56 | +0.00% | $8.9B | — |
| BDUUFBangkok Dusit Medical Services Public Company Limited | $0.64 | +0.00% | $10.2B | — |
| BIOVFSwedish Orphan Biovitrum AB (publ) | $48.00 | +0.00% | $16.6B | — |
| CHJTFCSPC Pharmaceutical Group Limited |
RECORDATI INDUSTRIA CHIM
No one on the platform currently holds RCDTF.
No tracked institution reports a position in RCDTF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-19 | $0.7100 | 2026-05-20 |
| 2025-11-25 | $0.6300 | 2025-11-26 |
| 2025-05-20 | $0.6700 | 2025-05-21 |
| 2024-11-19 | $0.6000 | 2024-11-20 |
| 2024-05-20 | $0.6300 | 2024-05-22 |
| 2023-11-20 | $0.5700 | 2023-11-22 |
| Execution date | Ratio |
|---|---|
| 2005-04-18 | 4-for-1 |
No one on the platform has traded RCDTF yet.
| $0.98 |
| +0.00% |
| $11.2B |
| — |
| CSPCYCSPC Pharmaceutical Group Limited | $3.51 | -1.45% | $10.1B | — |
| GIFLFGrifols, S.A. | $10.45 | +0.00% | $7.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 29.0× earnings vs its 26.5× historical median P/E.
Fair value ≈ $53.03 · price $58.00 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.